52602-68-3

Usage

Uses

Used in Pharmaceutical Industry:
6-chloro-N-methyl-pyrimidine-4,5-diamine is used as a chemical intermediate for the synthesis of various pharmaceuticals, including antiviral and antitumor drugs. Its unique structure allows for the development of new therapeutic agents with potential applications in treating viral infections and cancer.
Used in Agrochemical Industry:
6-chloro-N-methyl-pyrimidine-4,5-diamine is used as a building block in the development of new pesticides. Its incorporation into agrochemical formulations can lead to the creation of innovative products with enhanced efficacy and selectivity in controlling pests and diseases in agriculture.

InChI:InChI=1/C5H7ClN4/c1-8-5-3(7)4(6)9-2-10-5/h2H,7H2,1H3,(H,8,9,10)

Upstream product

• 5413-85-4 5-amino-4,6-dichloropyridimine 
• 74-89-5 methylamine 
• 23126-82-1 6-chloro-N-methyl-5-nitropyrimidin-4-amine 

Downstream Products

• 875-31-0 9-methylhypoxanthine 
• 100123-83-9 6-chloro-N⁴-methyl-5-(4-nitro-benzylidene)-pyrimidine-4,5-diyldiamine 
• 2346-74-9 6-chloro-9-methyl-9H-purine 
• 13784-17-3 5-amino-4-methylaminopyrimidine 
• 21323-71-7 6-Chlor-9-methyl-8-azapurin 
• 868163-77-3 6-chloro-9-methyl-8-(4-hydroxyphenyl)-9H-purine 
• 1354550-29-0 2-[4-(9-methyladenin-8-yl)phenoxy]-N-(4-fluorophenyl)acetamide 
• 1354550-30-3 2-[4-(9-methyladenin-8-yl)phenoxy]-N-(4-tolyl)acetamide 
• 1354550-31-4 2-[4-(9-methyladenin-8-yl)phenoxy]-N-(2,6-dimethylphenyl)acetamide 
• 1354550-32-5 2-[4-(9-methyladenin-8-yl)phenoxy]-N-(4-nitrophenyl)acetamide 
• 1354550-20-1 9-methyl-8-(4-hydroxyphenyl)adenine 
• 1354550-21-2 9-methyl-8-(4-benzyloxyphenyl)adenine 
• 1354550-22-3 9-methyl-8-[4-(4-fluorobenzyloxy)phenyl]adenine 
• 1354550-23-4 9-methyl-8-[4-(4-methylbenzyloxy)phenyl]adenine 

Relevant academic research and scientific papers

New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases

The synthesis of 9-alkyl substituted adenine derivatives presenting aromatic groups and cycloalkyl rings in 8- and N6-position, respectively, is reported. The compounds were tested with radioligand binding studies showing, in some cases, a low

INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

New 9-methyl-8-(4-hydroxyphenyl)adenine derivatives as A1 adenosine receptor antagonists

A new series of 9-methyladenines, bearing different bulky groups at the 8-position, were prepared and their affinity for the four human adenosine receptor subtypes were evaluated. All the synthesized compounds showed affinities at the A1, Asub

Novel 8-arylated purines as inhibitors of glycogen synthase kinase

A series of 8-arylated purine derivatives bearing either an aniline or an alkyl amide at position 6 were found to inhibit glycogen synthase kinase-3,with good selectivity over ten kinases. Molecular modeling studies indicated that the most active compounds (8a and 8e),adopt a planar conformation,close to the shape of AMPPNP in the crystal structure of GSK-3. These compounds are stabilized by hydrophobic contacts between the 8-aromatic group and the protein adenine pocket and by electrostatic contacts.

AMINOPYRIMIDINAMIDES AS PESTICIDES

The present application relates to novel aminopyrimidinamides, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.

Heterocyclic Compounds Useful as RAF Kinase Inhibitors

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation

The invention relates to compounds containing a N-heteroaryl moiety, which is linked via oxygen, sulfur or nitrogen, or via a methylene bridge and oxygen, sulfur or nitrogen to a fused ring moiety, in particular to the 1,2,3-triazolo[4,5-d]pyrimidine-7-yl radical. The invention also relates to a process for the preparation of said compounds and the use thereof in drugs for the treatment of NAD(P)H oxidases-related diseases and disorders and inhibition of platelet activation.